Identification of the antigens predominantly reacted with serum from patients with hepatocellular carcinoma

Cancer

Volumn 97, Issue 10, 2003, Pages 2474-2479

  Uemura, Masayuki ^a   Nouso, Kazuhiro ^a   Kobayashi, Yoshiyuki ^a   Tanaka, Hironori ^a   Nakamura, Shin Ichiro ^a   Higashi, Toshihiro ^b   Ono, Toshiro ^a   Nakayama, Eiichi ^a   Hanafusa, Tadashi ^a   Shiratori, Yasushi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Okayama Citizens Hospital   (Japan)

Author keywords

4 integrin binding protein; Hepatocellular carcinoma; Ribosomal protein L30; Tat binding protein 1; Tumor markers; Tumor associated antigens

Indexed keywords

ANTIBODY; ANTIGEN ROCK 1; ANTIGEN SART1; BETA4 INTEGRIN BINDING PROTEIN; BINDING PROTEIN; HEAT SHOCK PROTEIN; PLAKOGLOBIN; PROTEIN P27; PROTEIN P57; RIBOSOMAL PROTEIN L30; RIBOSOME PROTEIN; TAT BINDING PROTEIN 1; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; COMPLEMENTARY DNA; PRIMER DNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA LIBRARY; DNA SEQUENCE; FEMALE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; MALE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SERUM; TUMOR IMMUNITY; VIRUS HEPATITIS; ALCOHOL LIVER DISEASE; CASE CONTROL STUDY; CELL TRANSFORMATION; GENE LIBRARY; GENETICS; HEPATITIS B; HEPATITIS C; IMMUNOLOGY; LIVER TUMOR;

AGED; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; DNA PRIMERS; DNA, COMPLEMENTARY; FEMALE; GENE LIBRARY; HEPATITIS B; HEPATITIS C; HEPATITIS, ALCOHOLIC; HUMANS; LIVER NEOPLASMS; MALE; TUMOR MARKERS, BIOLOGICAL;

EID: 0038709282     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11374     Document Type: Article

References (32)

1. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology. 1992;15:948-963.
2. Shiratori Y, Shiina S, Imamura M, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B-and C-viral infection in Japan. Hepatology. 1995;22(4 Pt 1): 1027-1033.
3. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet. 2000;356: 802-807.
4. Imaoka S, Sasaki Y, Ishikawa O, et al. Immunochemotherapy in human hepatocellular carcinoma using the streptococcal agent OK-432. J Clin Oncol. 1986;4:1645-1651.
5. Oka M, Hazama S, Yoshino S, et al. Intraarterial combined immunochemotherapy for unresectable hepatocellular carcinoma: preliminary results. Cancer Immunol Immunother. 1994;38:194-200.
6. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332.
7. Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 1999;80:219-230.
8. Wang F, Bade E, Kuniyoshi C, et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res. 1999;5:2756-2765.
9. Jager E, Gnjatic S, Nagata Y, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA. 2000;97:12198-12203.
10. Kariyama K, Higashi T, Kobayashi Y, et al. Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma. Br J Cancer. 1999;81:1080-1087.
11. Kobayashi Y, Higashi T, Nouso K, et al. Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma. J Hepatol. 2000;32:612-617.
12. Tureci O, Sahin U, Schobert I, et al. The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res. 1996;56:4766-4772.
13. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 1997;94: 1914-1918.
14. Scanlan MJ, Chen YT, Williamson B, et al. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer. 1998;76:652-658.
15. Stenner-Liewen F, Luo G, Sahin U, et al. Definition of tumor-associated antigens in hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2000;9:285-290.
16. Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 1998;187:265-270.
17. Uemura M, Nonsok, Kobayashi Y, et al. Antigens recognized by autologous antibody in patients with hepatocellular carcinoma. Hepatology. 2001;34(4 Pt. 2)176A.
18. Shichijo S, Nakao M, Imai Y, et al. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med. 1998;187:277-288.
19. Lee MH, Yang HY. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci. 2001;58: 1907-1922.
20. Genda T, Sakamoto M, Ichida T, et al. Cell motility mediated by rho and Rho-associated protein kinase plays a critical role in intrahepatic metastasis of human hepatocellular carcinoma. Hepatology. 1999;30:1027-1036.
21. Wadhwa R, Takano S, Mitsui Y, Kaul SC. NIH 3T3 cells malignantly transformed by mot-2 show inactivation and cytoplasmic sequestration of the p53 protein. Cell Res. 1999; 9:261-269.
22. Kolligs FT, Kolligs B, Hajra KM, et al. Gamma-catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta-catenin. Genes Dev. 2000;14:1319-1331.
23. Wataba K, Saito T, Fukunaka K, Ashihara K, Nishimura M, Kudo R. Over-expression of heat shock proteins in carcinogenic endometrium. Int J Cancer. 2001;91:448-456.
24. Ishii M, Izumi J, Fujiwara H, Ito M, Hamada M. Immunoblotting detection of gamma-catenin (plakoglobin) antibody in the serum of a patient with paraneoplastic pemphigus. Br J Dermatol. 2001;144:377-379.
25. Trieb K, Gerth R, Holzer G, Grohs JG, Berger P, Kotz R. Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy. Br J Cancer. 2000;82:85-87.
26. Nelbock P, Dillon PJ, Perkins A, Rosen CA. A cDNA for a protein that interacts with the human immunodeficiency virus Tat transactivator. Science. 1990;248:1650-1653.
27. DeMartino GN, Proske RJ, Moomaw CR, et al. Identification, purification, and characterization of a PA700-dependent activator of the proteasome. J Biol Chem. 1996;271:3112-3118.
28. Park BW, O'Rourke DM, Wang Q, et al. Induction of the Tat-binding protein 1 gene accompanies the disabling of oncogenic erbB receptor tyrosine kinases. Proc Natl Acad Sci USA. 1999;96:6434-6438.
29. Barak O, Aronheim A, Shaul Y. HBV X protein targets HIV Tat-binding protein 1. Virology. 2001;283:110-120.
30. Biffo S, Sanvito F, Costa S, et al. Isolation of a novel beta4 integrin-binding protein (p27(BBP)) highly expressed in epithelial cells. J Biol Chem. 1997;272:30314-30321.
31. Sanvito F, Vivoli F, Gambini S, et al. Expression of a highly conserved protein, p27BBP, during the progression of human colorectal cancer. Cancer Res. 2000;60:510-516.
32. Vaarala MH, Porvari KS, Kyllonen AP, Mustonen MV, Lukkarinen O, Vihko PT. Several genes encoding ribosomal proteins are over-expressed in prostate-cancer cell lines: confirmation of L7a and L37 over-expression in prostate-cancer tissue samples. Int J Cancer. 1998;78:27-32.